TD Cowen initiated coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Get Free Report) in a report issued on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $15.00 price target on the stock. TD Cowen’s price objective indicates a potential upside of 167.38% from the stock’s previous close.
Several other research firms have also recently commented on AVR. Barclays began coverage on shares of Anteris Technologies Global in a report on Tuesday. They set an “overweight” rating and a $22.00 price target on the stock. Cantor Fitzgerald initiated coverage on Anteris Technologies Global in a research report on Tuesday. They issued an “overweight” rating and a $9.00 target price on the stock.
Read Our Latest Analysis on Anteris Technologies Global
Anteris Technologies Global Stock Up 0.4 %
Anteris Technologies Global Company Profile
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
See Also
- Five stocks we like better than Anteris Technologies Global
- How to buy stock: A step-by-step guide for beginners
- NVIDIA is Still the Most Important Stock in the Market
- 5 Top Rated Dividend Stocks to Consider
- 2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Will Berkshire Hathaway Continue to Dominate in 2025?
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
